Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
作者： Olaf Oberschmidt , Stephan Kloess , Ulrike Koehl
关键词:
摘要: Primary human natural killer (NK) cells recognize and subsequently eliminate virus infected cells, tumor or other aberranT-cells. However, cancer are able to develop immune escape mechanisms undermine this control. To overcome obstacle, NK can be genetically modified express chimeric antigen receptors (CARs) in order improve specific recognition of surface markers (e. g. CD19, CD20, ErbB2). After target recognition, intracellular CAR domain signaling (CD3zeta, CD28, 4-1BB, 2B4) lead activation PI3K DNAX proteins (DAP10, DAP12) finally enhanced cytotoxicity, proliferation, and/or IFNgamma release. This mini-review summarizes both the first pre-clinical trials with engineered primary translational implications for “off-the-shelf-immunotherapy” treatment. Signal transduction as well optimization will described, becoming more a focal point interest addition redirected T-cells. Finally, strategies off-target effects discussed future clinical avoid attacking healthy tissues.
frontiersin.org
core.ac.uk
sci-hub.se 参考文章(95)
Katayoun Rezvani, Rayne H. Rouce, The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Frontiers in Immunology. ,vol. 6, pp. 578- 578 ,(2015) , 10.3389/FIMMU.2015.00578
Joachim P. Steinbach, Winfried S. Wels, Sabrina Genßler, Michael C. Burger, Congcong Zhang, Sarah Oelsner, Iris Mildenberger, Marlies Wagner, Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival OncoImmunology. ,vol. 5, ,(2016) , 10.1080/2162402X.2015.1119354
Garnet Suck, Yeh Ching Linn, Torsten Tonn, Natural Killer Cells for Therapy of Leukemia Transfusion Medicine and Hemotherapy. ,vol. 43, pp. 89- 95 ,(2016) , 10.1159/000445325
Xilin Chen, Jianfeng Han, Jianhong Chu, Lingling Zhang, Jianying Zhang, Charlie Chen, Luxi Chen, Youwei Wang, Hongwei Wang, Long Yi, J Bradley Elder, Qi-En Wang, Xiaoming He, Balveen Kaur, E Antonio Chiocca, Jianhua Yu, None, A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases Oncotarget. ,vol. 7, pp. 27764- 27777 ,(2016) , 10.18632/ONCOTARGET.8526
U Koehl, C Kalberer, J Spanholtz, DA Lee, JS Miller, S Cooley, M Lowdell, L Uharek, H Klingemann, A Curti, W Leung, E Alici, None, Advances in clinical NK cell studies: Donor selection, manufacturing and quality control OncoImmunology. ,vol. 5, ,(2016) , 10.1080/2162402X.2015.1115178
Lorenzo Moretta, Gabriella Pietra, Paola Vacca, Daniela Pende, Francesca Moretta, Alice Bertaina, Maria Cristina Mingari, Franco Locatelli, Alessandro Moretta, Human NK cells: From surface receptors to clinical applications. Immunology Letters. ,vol. 178, pp. 15- 19 ,(2016) , 10.1016/J.IMLET.2016.05.007
Nadja Müller, Susanne Michen, Stefanie Tietze, Katrin Töpfer, Alexander Schulte, Katrin Lamszus, Marc Schmitz, Gabriele Schackert, Ira Pastan, Achim Temme, Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma Journal of Immunotherapy. ,vol. 38, pp. 197- 210 ,(2015) , 10.1097/CJI.0000000000000082
Rachel A. Burga, Tuongvan Nguyen, Jane Zulovich, Sarah Madonna, Loyda Ylisastigui, Rohan Fernandes, Eric Yvon, Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells Cytotherapy. ,vol. 18, pp. 1410- 1421 ,(2016) , 10.1016/J.JCYT.2016.05.018
Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin KH Chow, Vita S Brawley, Tiara T Byrd, Simone Krebs, Stephen Gottschalk, Winfried S Wels, Matthew L Baker, Gianpietro Dotti, Maksim Mamonkin, Malcolm K Brenner, Jordan S Orange, Nabil Ahmed, None, Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. Journal of Clinical Investigation. ,vol. 126, pp. 3036- 3052 ,(2016) , 10.1172/JCI83416
Stephen J. Blake, William C. Dougall, John J. Miles, Michele W.L. Teng, Mark J. Smyth, Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical Cancer Research. ,vol. 22, pp. 5183- 5188 ,(2016) , 10.1158/1078-0432.CCR-16-0933